ACT-660602

• UNSPSC Description:

  ACT-660602 is an orally active antagonist of chemokine receptor (CXCR3) with an IC50 value of 204 nM. ACT-660602 inhibits T-cell migration and shows efficacy in acute lung ingury model. ACT-660602 can be used for autoimmune diseases research[1][2].

• Target Antigen:

  CXCR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/act-660602.html

• Solubility:

  DMSO : 110 mg/mL (ultrasonic)

• Smiles:

  FC(C1=NC=C(C2=C(N3C[C@@H](C)N(C(CN4N=C(C)N=C4C)=O)CC3)SC(C(F)(F)F)=N2)C=N1)(F)F

• Molecular Weight:

  534.48

• References & Citations:

  [1]Meyer EA, et al. Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases. J Med Chem. 2022 Aug 10.|[2]Caroff Eva, et al. Preparation of piperazinyltriazolylethanone derivatives for use as CXCR3 receptor modulators: World Intellectual Property Organization, WO2015011099. 2015-01-29.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1646267-59-5